-

AudioCure Pharma Receives Hearing Technology Innovator Award for its Innovative Compound AC102 for the Treatment of Sudden Hearing Loss

  • AudioCure Receives Hearing Technology Innovator Award for AC102 in Therapeutics Category
  • A Phase 2 clinical trial evaluating the efficacy, safety and tolerability of AC102 in patients with Sudden Sensorineural Hearing Loss is underway across Europe
original Dr. Reimar Schlingensiepen (left, CEO of AudioCure Pharma GmbH) and Prof. Hans Rommelspacher (founder and CSO) receive the award in the therapeutics category. (Photo: AudioCure Pharma)

Dr. Reimar Schlingensiepen (left, CEO of AudioCure Pharma GmbH) and Prof. Hans Rommelspacher (founder and CSO) receive the award in the therapeutics category. (Photo: AudioCure Pharma)

BERLIN--(BUSINESS WIRE)--AudioCure Pharma GmbH announced today that it has been awarded for its innovative compound AC102 by the Hearing Technology Innovator Awards™, honoring technological innovation and breakthroughs in the hearing industry.

AudioCure's AC102 receives Hearing Technology Innovator Award™ for groundbreaking hearing loss treatment. A pan-European Phase 2 trial is ongoing.

Share

AudioCure is developing the therapeutic small molecule AC102 to treat hearing impairments including Sudden Sensorineural Hearing Loss (SSNHL). While corticosteroids are the standard treatment, health authorities have never approved them as there is no clear evidence of a clinically relevant benefit to the patient. AudioCure is conducting extensive research to develop targeted and effective therapies to address this high unmet medical need. In preclinical hearing loss models, a single application of AC102 in the middle ear almost completely restores hearing, strongly outperforming multiple doses of corticosteroid therapy. After AC102 was demonstrated as safe and well-tolerated in healthy volunteers, a Europe-wide Phase 2 clinical trial is currently underway evaluating the efficacy of AC102 compared to corticosteroids. Patients with severe to profound SSNHL can be enrolled within 5 days of symptom onset at up to 50 study centers, including in Austria, Germany, The Czech Republic, The Netherlands, Poland and Serbia.

"The Innovator Awards aim to acknowledge the individuals and organizations that transform groundbreaking hearing care concepts into reality," explained Dr. Robert Traynor, member of the 2023 Awards program judge's panel. "Companies like AudioCure are playing a pivotal role in advancing innovation throughout the industry."

Reimar Schlingensiepen, CEO of AudioCure, said: “Receiving the Hearing Technology Innovator Award underscores the urgent need for advanced solutions in treating conditions like SSNHL. It also honors the groundbreaking innovation by our founder, Prof. Hans Rommelspacher. Our ongoing Phase 2 clinical trial represents a significant step towards a transformative solution. This recognition fuels our commitment to redefine the standards-of-care in hearing therapeutics.”

For further information, please visit https://www.audiocure.com/hhtm/

Contacts

AudioCure Pharma GmbH
Frauke Luers
Phone: +49 30 2218 397-0
E-Mail: pr@ac-clinical.com
Web: www.audiocure.com

Industry:

AudioCure Pharma GmbH

Release Summary
AudioCure's AC102 receives Hearing Technology Innovator Award for groundbreaking hearing loss treatment. A pan-European Phase 2 trial is ongoing.
Release Versions
EnglishSpanish (Summary)GermanFrenchItalian (Summary)Dutch (Summary)

Contacts

AudioCure Pharma GmbH
Frauke Luers
Phone: +49 30 2218 397-0
E-Mail: pr@ac-clinical.com
Web: www.audiocure.com

More News From AudioCure Pharma GmbH

Tinnitus Research: Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model

ERLANGEN, Germany & BERLIN--(BUSINESS WIRE)--The novel compound AC102 almost completely reversed tinnitus in a preclinical model after a single dose. At the same time, the damaged connections between the auditory nerve and inner ear sensory cells were restored. These findings were recently published in the prestigious International Journal of Molecular Sciences in a joint study conducted by Erlangen University Hospital and Berlin-based drug developer AudioCure. As there is currently no causal t...

InfectoPharm Invests in AudioCure to Advance Innovative Hearing Loss Therapy

HEPPENHEIM, Germany & BERLIN--(BUSINESS WIRE)--There is currently no drug approved worldwide for the treatment of sudden hearing loss. However, preclinical and clinical phase-1-studies with the innovative drug candidate AC102 have been promising. AudioCure Pharma, a Berlin-based start-up supported by investors, is driving forward research and development. Now, InfectoPharm, a successful medium-sized company, is joining as a new and essential competence partner. The Heppenheim-based ENT speciali...

Sudden Hearing Loss Study Reaches Milestone: AudioCure Pharma Enrolls More Than Half of the Patients in AC102 Study

BERLIN--(BUSINESS WIRE)--Berlin-based start-up AudioCure Pharma has enrolled more than 50% of the planned patients in its ongoing Phase 2 clinical trial. The aim of the study is to test the efficacy of the new compound AC102 for the treatment of sudden hearing loss. As sudden hearing loss is usually treated with non-specific corticoids that are not approved for this indication or for which there is no clear evidence of efficacy, there is an urgent need for new therapies. This enrollment milesto...
Back to Newsroom